Pacjentka z nowo zdiagnozowaną rzutowo-remisyjną postacią stwardnienia rozsianego, u której zastosowano leczenie fumaranem dimetylu de novo – opis przypadku Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
stwardnienie rozsiane, postać rzutowo-remisyjna, fumaran dimetylu
##plugins.themes.bootstrap3.article.main##
Abstrakt
Obecnie w leczeniu rzutowo-remisyjnej postaci stwardnienia rozsianego dysponujemy kilkunastoma lekami wpływającymi na przebieg choroby o różnej skuteczności i profilu bezpieczeństwa. Optymalne dobranie leku i rozpoczęcie takiej terapii tuż po rozpoznaniu choroby daje szansę na zatrzymanie jej progresji i utrzymania niskiego odsetka rzutów. Celem pracy jest opis przypadku pacjentki z rzutowo-remisyjną postacią stwardnienia rozsianego, u której zastosowano leczenie fumaranem dimetylu de novo.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359: 1221-31.
2. Gold R, Giovannoni G, Phillips JT et al. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther. 2016; 5(1): 45-57.
3. Berger T, Brochet B, Brambilla L et al. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. Mult Scler J Exp Transl Clin. 2019; 5(4): 2055217319887191.
4. Gold R. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult Scler. 2022; 28(5): 801-16.
5. Gold R, Giovannoni G, Phillips JT et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler. 2015; 21(1): 57-66.
6. Gold R, Arnold DL, Bar-Or A et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020; 13: 1756286420915005.
7. Poulos C, Wakeford C, Kinter E et al. Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. Mult Scler J Exp Transl Clin. 2020; 6(1): 2055217320910778.
8. Goodin DS, Bates D. Treatment of early multiple sclerosis: The value of treatment initiation after a first clinical episode. Mult Scler. 2009; 15(10): 1175-82.
9. Mitzi J, Amezcua L, Chinea A et al. Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM. Neurol Ther. 2023; 12(5): 1669-82.
10. Kresa-Reahl K, Repovic P, Robertson D et al. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Clin Ther. 2018; 40(12): 2077-87.
2. Gold R, Giovannoni G, Phillips JT et al. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther. 2016; 5(1): 45-57.
3. Berger T, Brochet B, Brambilla L et al. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. Mult Scler J Exp Transl Clin. 2019; 5(4): 2055217319887191.
4. Gold R. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult Scler. 2022; 28(5): 801-16.
5. Gold R, Giovannoni G, Phillips JT et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler. 2015; 21(1): 57-66.
6. Gold R, Arnold DL, Bar-Or A et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020; 13: 1756286420915005.
7. Poulos C, Wakeford C, Kinter E et al. Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. Mult Scler J Exp Transl Clin. 2020; 6(1): 2055217320910778.
8. Goodin DS, Bates D. Treatment of early multiple sclerosis: The value of treatment initiation after a first clinical episode. Mult Scler. 2009; 15(10): 1175-82.
9. Mitzi J, Amezcua L, Chinea A et al. Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM. Neurol Ther. 2023; 12(5): 1669-82.
10. Kresa-Reahl K, Repovic P, Robertson D et al. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Clin Ther. 2018; 40(12): 2077-87.